- Clinical Trials
Presentation to Highlight the Promise of Novel Gene Therapies to Transform Cancer and Diabetes Treatments
Thomas Gallagher, Senior VP of Intellectual Property and Licensing, to provide insight into IP best practices to early-stage companies
Inventor of the Company’s licensed diabetes gene therapy technology to provide leadership, strategy for diabetes program
An experimental gene therapy developed by Texas biotech Genprex will be paired with AstraZeneca’s Tagrisso and Merck & Co’s Keytruda – both leading their respective drug classes in the treatment of non-small cell lung cancer (NSCLC).
Genprex announced that quaratusugene ozeplasmid (Reqorsa) will be studied in two new trials, in which non-small cell lung cancer patients with specific molecular markers will receive its investigational drug combined with osimertinib (AstraZeneca’s Tagrisso) or pembrolizumab (Merck’s Keytruda).
New branding will support upcoming combination clinical trials, including the Company’s trial combining REQORSA™ immunogene therapy drug with AstraZeneca’s Tagrisso®, which received FDA Fast Track Designation earlier in 2020
Approval of new name marks important branding milestone and aligns with the program’s overall progress
Mr. Chapdelaine’s promotion follows the Company’s achievement of key manufacturing milestones to support upcoming clinical trials
Genprex’s President and Chief Executive Officer, Rodney Varner, will be delivering the company’s corporate presentation followed by a Q&A session with participants.
The 2020 Cell and Gene Meeting on the Mesa will be delivered in a virtual format over the course of five days where attendees will be able to watch company presentations on-demand, in addition to two live-streaming panels each day.